Log in to save to my catalogue

Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related im...

Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related im...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_67066c16a067456492ca854e513c78f6

Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities

About this item

Full title

Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities

Publisher

London: Nature Publishing Group UK

Journal title

Scientific reports, 2024-05, Vol.14 (1), p.10868-15, Article 10868

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Therapeutic antibodies have been developed to target amyloid-beta (Aβ), and some of these slow the progression of Alzheimer’s disease (AD). However, they can also cause adverse events known as amyloid-related imaging abnormalities with edema (ARIA-E). We investigated therapeutic Aβ antibody binding to cerebral amyloid angiopathy (CAA) fibrils isola...

Alternative Titles

Full title

Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_67066c16a067456492ca854e513c78f6

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_67066c16a067456492ca854e513c78f6

Other Identifiers

ISSN

2045-2322

E-ISSN

2045-2322

DOI

10.1038/s41598-024-61691-2

How to access this item